- Home
- ASM vs XNCR Comparison
ASM vs XNCR Comparison
Compare ASM & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASM | XNCR |
|---|---|---|
| Founded | 1968 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.7M | 881.9M |
| IPO Year | 2005 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ASM | XNCR |
|---|---|---|
| Price | $7.80 | $11.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $8.18 | ★ $22.89 |
| AVG Volume (30 Days) | ★ 4.3M | 579.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $35.91 | N/A |
| Revenue Next Year | $62.02 | $6.52 |
| P/E Ratio | $67.93 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $1.32 | $6.92 |
| 52 Week High | $11.99 | $18.69 |
Technical Indicators
Market Signals| Indicator | ASM | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 41.63 | 42.78 |
| Support Level | $3.70 | $11.02 |
| Resistance Level | $11.99 | $12.58 |
| Average True Range (ATR) | 0.63 | 0.89 |
| MACD | -0.24 | 0.04 |
| Stochastic Oscillator | 14.65 | 17.35 |
Price Performance
Historical ComparisonAbout ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.